Lunit Venture Capital

Lunit develops medical AI software applied across the cancer care pathway, from population screening through diagnosis, treatment decisions and drug development. Its product portfolio is organized into two families: Lunit INSIGHT for cancer screening, which includes MMG (2D mammography), DBT (3D digital breast tomosynthesis) and CXR (chest X-ray) analysis alongside workflow tools such as Live, Analytics, Scorecard, Patient Hub, Risk Pathways and an image-based risk product described as 510(k) pending; and Lunit SCOPE for precision oncology, which includes SCOPE IO for tumor microenvironment analysis, the SCOPE IHC Suite for immunohistochemistry quantification, SCOPE uIHC, SCOPE HER2, SCOPE PD-L1, and SCOPE GP for genotype prediction.

The company positions its offering as a modular platform that connects multimodal clinical data and interoperable solutions for integration into existing radiology and pathology workflows, with models trained on global datasets and described as evolving toward foundation models. Reported scale includes more than 10,000 customer sites across more than 70 countries, over 700 publications and more than 100 partnerships.

Business model

Lunit supplies AI diagnostic and biomarker software to healthcare providers for screening and diagnosis, and works with biopharmaceutical partners on oncology biomarker and companion diagnostic strategy, including clinical trial support and global deployment.

Traction

Reported metrics include more than 10,000 customer sites, presence in over 70 countries, more than 700 publications and over 100 partnerships. The company also reported that its breast imaging AI is used at more than 330 sites covering over one million annual screenings, and it presents multiple research studies at oncology conferences including AACR 2026 and ASCO 2026.